Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939004 | 0.85 | APP (0.68) | CDK1PDE5AAPPESR1PDE4A | |
| SCHEMBL20164489 | 0.83 | ACHE (0.56) | CDK1APPCCNE1CDK2CCNE2 | |
| Hydrochloric Acid SCHEMBL20164486 | 0.82 | BCHE (0.54) | CDK1APPCCNE1CDK2CCNE2 | |
| SCHEMBL20164718 | 0.81 | CDK2 (0.37) | CDK1PDE5AAPPESR1CCNE1 | |
| SCHEMBL20164596 | 0.79 | APP (0.56) | CDK1PDE5AAPPESR1PDE4A | |
| SCHEMBL20164422 | 0.78 | ESR1 (0.33) | CDK1ESR1CCNE1CDK2CDK5 | |
| SCHEMBL7973136 | 0.76 | CCNE2 (0.58) | CDK1PDE5AAPPCCNE1CDK2 | |
| SCHEMBL20164648 | 0.76 | KMT2A (0.43) | ESR1PDE10A | |
| SCHEMBL20164493 | 0.75 | CDK1 (0.43) | CDK1PDE5APDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL20164490 | 0.74 | CDK1 (0.42) | CDK1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | CDK1 3077/4885PDE5A 10/4885APP 2716/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | CDK1 3444/4885PDE5A 14/4885APP 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.